Evidence map›Paper›PMID 29949100›Full record

ArticleDrug safety2018

What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects.

Rike van Eekeren, Leàn Rolfes, Andries S Koster, Lara Magro, Gurumurthy Parthasarathi, Hussain Al Ramimmy, Tim Schutte, Daisuke Tanaka, Eugène van Puijenbroek, Linda Härmark

Open access · hybridAbstract read
In one paragraph

Article in Drug safety, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
6.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Health outcomes and policy in pharmay curricula among Arab countries: An evaluation of 191 academic institutions.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021
    Article
  18. Pharmacovigilance: Basic concepts and an overview of the system in Oman.Sultan Qaboos University medical journal · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 5 countries.

Rike van EekerenNetherlands Pharmacovigilance Centre Lareb, WHO Collaborating Centre For Pharmacovigilance in Education and Patient Reporting, Goudsbloemvallei 7, 5237 MH, 's-Hertogenbosch, The Netherlands. r.van.eekeren-buiten@rug.nl.ORCID http://orcid.org/0000-0002-2560-1158
Leàn RolfesNetherlands Pharmacovigilance Centre Lareb, WHO Collaborating Centre For Pharmacovigilance in Education and Patient Reporting, Goudsbloemvallei 7, 5237 MH, 's-Hertogenbosch, The Netherlands.
Andries S KosterDepartment of Pharmaceutical Sciences, University of Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0001-7772-4654
Lara MagroDepartment of Diagnostics and Public Health, Section of Pharmacology, University of Verona, Verona, Italy.
Gurumurthy ParthasarathiJSS College of Pharmacy, JSS University, Mysore, India.
Hussain Al RamimmyDepartment of Pharmacovigilance and Drug Information, Directorate General of Pharmaceutical Affairs and Drug Control, Ministry of Health, Muscat, Sultanate of Oman.
Tim SchutteDepartment of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-4096-0917
Daisuke TanakaWHO, Geneva, Switzerland.
Eugène van PuijenbroekNetherlands Pharmacovigilance Centre Lareb, WHO Collaborating Centre For Pharmacovigilance in Education and Patient Reporting, Goudsbloemvallei 7, 5237 MH, 's-Hertogenbosch, The Netherlands.
Linda HärmarkNetherlands Pharmacovigilance Centre Lareb, WHO Collaborating Centre For Pharmacovigilance in Education and Patient Reporting, Goudsbloemvallei 7, 5237 MH, 's-Hertogenbosch, The Netherlands.
University of Groningen · NLAmsterdam UMC Location Vrije Universiteit Amsterdam · NLJSS Academy of Higher Education and Research · INMinistry of Health · OMNetherlands Pharmacovigilance Centre Lareb · NLUniversity of Verona · ITUtrecht University · NLWorld Health Organization · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adverse drug reactions (ADRs) can cause serious health problems, as shown in studies about drug-related hospitalizations. To build knowledge of and raise awareness about ADRs among healthcare professionals, more education in the field of ADRs and pharmacovigilance (PV) is needed. No standard exists for teaching PV at universities for medical, pharmacy, dentistry and nursing students, so a core curriculum needs to be developed to teach important aspects of PV to students. In September 2016, a stakeholders' meeting was initiated on behalf of the World Health Organization (WHO) and organized by the Netherlands Pharmacovigilance Centre Lareb. This meeting addressed and agreed on the PV competencies students need to develop and what key aspects of the subject should be taught. Five key aspects were identified: understanding the importance of PV in the context of pharmacotherapy, and preventing, recognizing, managing and reporting ADRs. Since time and resources for PV education are limited, elements of the WHO PV core curriculum for university teaching were designed to be integrated into existing courses but can be used as a stand-alone programme. The basis of and outline for the WHO PV core curriculum for university teaching are addressed in this paper. It is expected that PV competencies for students are vital for their contribution to safe use of medicines in the future. In addition, this article aims to stimulate discussion on this subject and promote collaboration between universities, national PV centres and other stakeholders to integrate key aspects of PV in their educational programmes.

Indexed as

PharmacovigilanceAdverse Drug Reaction Reporting SystemsCurriculumDocumentationDrug-Related Side Effects and Adverse ReactionsHealth Knowledge, Attitudes, PracticeHealth PersonnelHumansNetherlandsProfessional CompetenceTime FactorsWorld Health Organization

Identifiers

PMID29949100
PMCPMC6182454
OpenAlexW2807713065

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.